332 related articles for article (PubMed ID: 29027825)
1. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.
Jakubowiak AJ; Houisse I; Májer I; Benedict Á; Campioni M; Panjabi S; Ailawadhi S
Expert Rev Hematol; 2017 Dec; 10(12):1107-1119. PubMed ID: 29027825
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
Orlowski RZ; Moreau P; Niesvizky R; Ludwig H; Oriol A; Chng WJ; Goldschmidt H; Yang Z; Kimball AS; Dimopoulos M
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):522-530.e1. PubMed ID: 31160237
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.
Kumar SK; Majer I; Panjabi S; Medhekar R; Campioni M; Dimopoulos MA
Expert Rev Hematol; 2020 Jun; 13(6):687-696. PubMed ID: 32249621
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR.
Dimopoulos M; Siegel D; White DJ; Boccia R; Iskander KS; Yang Z; Kimball AS; Mezzi K; Ludwig H; Niesvizky R
Blood; 2019 Jan; 133(2):147-155. PubMed ID: 30478094
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Möller J; Nicklasson L; Murthy A
J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
Goldschmidt H; Moreau P; Ludwig H; Niesvizky R; Chng WJ; Joshua D; Weisel K; Spencer A; Orlowski RZ; Feng S; Iskander KS; Dimopoulos MA
Leuk Lymphoma; 2018 Jun; 59(6):1364-1374. PubMed ID: 28937327
[TBL] [Abstract][Full Text] [Related]
11. Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR.
Zeng X; Peng L; Peng Y; Tan C; Wan X
Clin Ther; 2020 Feb; 42(2):251-262.e5. PubMed ID: 31973936
[TBL] [Abstract][Full Text] [Related]
12. Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
Dolph M; Tremblay G; Leong H
Pharmacoeconomics; 2021 Nov; 39(11):1309-1325. PubMed ID: 34368938
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
Ludwig H; Moreau P; Dimopoulos MA; Mateos MV; Kaiser M; Hajek R; Feng S; Cocks K; Buchanan J; Weisel K
Blood Cancer J; 2019 Feb; 9(3):23. PubMed ID: 30796199
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Patel KK; Parker T; Di M; Bar N; Huntington SF; Giri S
Leuk Lymphoma; 2021 Nov; 62(11):2777-2784. PubMed ID: 34151696
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials.
Weisel K; Majer I; DeCosta L; Oriol A; Goldschmidt H; Ludwig H; Campioni M; Szabo Z; Dimopoulos M
Leuk Lymphoma; 2020 Jan; 61(1):37-46. PubMed ID: 31640435
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X
Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.
Carlson JJ; Guzauskas GF; Chapman RH; Synnott PG; Liu S; Russo ET; Pearson SD; Brouwer ED; Ollendorf DA
J Manag Care Spec Pharm; 2018 Jan; 24(1):29-38. PubMed ID: 29290170
[TBL] [Abstract][Full Text] [Related]
20. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.
Moreau P; Joshua D; Chng WJ; Palumbo A; Goldschmidt H; Hájek R; Facon T; Ludwig H; Pour L; Niesvizky R; Oriol A; Rosiñol L; Suvorov A; Gaidano G; Pika T; Weisel K; Goranova-Marinova V; Gillenwater HH; Mohamed N; Aggarwal S; Feng S; Dimopoulos MA
Leukemia; 2017 Jan; 31(1):115-122. PubMed ID: 27491641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
